Input 2020.12.28 15:55 | Revision 2020.12.28 16:22
According to Celltrion on the 28th, the company sent a text message to employees the day before and sent Celltrion, the three listed companies of the Celltrion Group, Celltrion Healthcare (091990), Celltrion Pharmaceutical (068760)It was announced that it would prohibit the sale of stock certificates. Family members were also included in the transaction ban, and asked the company to notify the company in advance if it was unavoidable.
An official from Celltrion said, “With the development of the COVID-19 treatment, the stock trading of executives and employees has not only become a target of social interest, but can lead to legal issues.” He said. He added, “We absolutely prohibit internal sharing and external transmission of information acquired regarding corona treatment. Please note that,” he said. “If you need to buy or sell stocks, please be sure to contact the IR department before trading.”
Celltrion, which announced last month that it has completed recruiting and administering patients for global phase 2 clinical trials of’CT-P59 (regdanvimab)’, a corona19 antibody treatment, plans to apply for conditional approval from the Ministry of Food and Drug Safety this week. Until now, Celltrion has revealed that it plans to apply for conditional approval from the Food and Drug Administration within this year.
“Celltrion is ready to apply for conditional approval from the Ministry of Food and Drug Safety for CT-P59″ at the ‘2020 Korea Bio Investment Conference (KBIC)’ held at Dragon City, Hangang-ro, Seoul on the 28th. ” The application for conditional approval will be made within this year.” He emphasized, “We have confirmed that CT-P59 actually works even with the mutated Corona 19 virus.” Celltrion plans to apply for a formal product license next year.
Meanwhile, it has been confirmed that some executives of Celltrion Group recently disposed of some of Celltrion’s shares.
Celltrion announced on the 24th that it has sold a total of 30,000 shares by eight executives and relatives from last month to this month.
Heon-young Yoo, Vice Chairman of Celltrion Holdings, sold 5,000 shares on the 9th and 10th of this month on the 9th and 10th, and sold a total of 10,000 shares. Baek Kyung-min, director in charge of drug safety at Celltrion, sold a total of 7078 shares on the 12th and 17th of last month. On the 7th and 9th of this month, Lee Sang-yoon, head of Celltrion’s global operations division, sold 4,000 shares on the 7th and 9th of this month, and Kim Bon-joong, head of the chemical product development division, on the 3rd of this month. Outside director Kim Geun-young sold 3,000 shares on the 22nd of this month.